Senthil Lingaratnam

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Systematic Review

Top Venues

Clinical and translational science

Journal of pharmaceutical policy and practice

This page only lists publications with an associated author ORCID identifier.

Publications

Senthil Lingaratnam, Mahek Shah, Joseph A Nicolazzo, Michael Michael, John Francis Seymour, Paul A James, Smaro Lazarakis, Sherene Loi, Carl M J Kirkpatrick
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer. Clinical and translational science 17 (5) (2024)
Senthil Lingaratnam, Safeera Yasmeen Hussainy, Alexandra Murphy, Cale Perrin, Melbin Samuvel, Elahe Mehrvarz, Chiao Xin Lim, John Zalcberg
Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review. Journal of pharmaceutical policy and practice 17 (1) (2024)
Senthil Lingaratnam, Mahek Shah, Joseph A Nicolazzo, Michael Michael, John Francis Seymour, Paul A James, Smaro Lazarakis, Sherene Loi, Carl M J Kirkpatrick
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer. Clinical and translational science 17 (5) (2024)
Senthil Lingaratnam, Mahek Shah, Joseph A Nicolazzo, Michael Michael, John Francis Seymour, Paul A James, Smaro Lazarakis, Sherene Loi, Carl M J Kirkpatrick
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer. Clinical and translational science 17 (5) (2024)
Senthil Lingaratnam, Safeera Yasmeen Hussainy, Alexandra Murphy, Cale Perrin, Melbin Samuvel, Elahe Mehrvarz, Chiao Xin Lim, John Zalcberg
Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review. Journal of pharmaceutical policy and practice 17 (1) (2024)